References
- Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical
characteristics of coronavirus disease 2019 in China. N Engl J Med
2020. [Online ahead of print]. doi: 10.1056/ NEJMoa2002032.
- Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2
in Different Types of Clinical Specimens. JAMA 2020. [Online ahead
of print]. doi: 10.1001/jama.2020.378.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and
risk factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study. Lancet 2020;395:1054-1062.
- Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma
inflammatory cytokines and chemokines in severe acute respiratory
syndrome. Clin Exp Immunol 2004;136:95-103.
- Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into
the eye of the cytokine storm. Microbiol Mol Biol Rev 2012;76:16-32.
- Wang WK, Chen SY, Liu IJ, Kao CL, Chen HL, Chiang BL, et al. Severe
Acute Respiratory Syndrome Research Group of the National Taiwan
University College of Medicine/NTU Hospital. Temporal relationship of
viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical
progression in patients with severe acute respiratory syndrome. Clin
Infect Dis 2004;39:1071-5.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia
outbreak associated with a new coronavirus of probable bat origin.
Nature 2020;579:270-273.
- Letko M, Marzi A, Munster V. Functional assessment of cell entry and
receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses.
Nat Microbiol 2020;5:562-569.
- Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al.
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung
inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2):
anti-inflammatory strategies. J Biol Regul Homeost Agents 2020;34:1.
- Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Clinical and
computed tomographic imaging features of novel coronavirus pneumonia
caused by SARS-CoV-2. J Infect 2020;80:394-400.
- Channappanavar R, Perlman S. Pathogenic human coronavirus infections:
causes and consequences of cytokine storm and immunopathology. Semin
Immunopathol 2017;39:529-539.
- Tanaka T, Kishimoto T. The biology and medical implications of
interleukin-6. Cancer Immunol Res 2014;2:288-94.
- Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with
chimeric antigen receptor engineered T cells. Cancer Letters
2014;343:172-178.
- Xiaoling Xu, Mingfeng Han, Tiantian Li, et al. Effective Treatment of
Severe COVID-19 Patients with Tocilizumab. ChinaXiv: 202003.00026v1;
TOCIVID-19.
- https://www.aifa.gov.it/sperimentazioni-cliniche-covid-19.
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH
Across Speciality Collaboration, UK. COVID-19: consider cytokine storm
syndromes and immunosuppression. Lancet 2020;395:1033-1034.
- Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of
mortality due to COVID-19 based on an analysis of data of 150 patients
from Wuhan, China. Intensive Care Med 2020. doi:
10.1007/s00134-020-05991-x.
- Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood
2002:99:3505-3516.
- Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases.
Autoimmun Rev 2007;6:457-463.
- Zandman-Goddard G, Orbach H, Agmon-Levin N, Boaz M, Amital H,
Szekanecz Z, et al. Hyperferritinemia is associated with serologic
antiphospholipid syndrome in SLE patients. Clin Rev Allergy Immunol
2011;44:23-30.
- Da Costa R, Szyper-Kravitz M, Szekanecz Z, Csepany T, Danko K, Shapira
Y, et al. Ferritin and prolactin levels in multiple sclerosis. Isr Med
Assoc J 2011;13:91-95.
- Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G,
et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin,
vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci
2007;1109:385-400.
- Bennett TD, Hayward KN, Farris RW, Ringold S, Wallace CA, Brogan TV.
Very high serum ferritin levels are associated with increased
mortality and critical care in pediatric patients. Pediatr Crit Care
Med 2011;12:e233-e236.
- Garcia PC, Longhi F, Branco RG, Piva JP, Lacks D, Tasker RC. Ferritin
levels in children with severe sepsis and septic shock. Acta Paediatr
2007:96:1829-1831.
- Demirkol D, Yildizdas D, Bayrakci B, Karapinar B, Kendirli T, Koroglu
TF, et al. Turkish Secondary HLH/MAS Critical Care Study Group:
Hyperferritinemia in the critically ill child with secondary
hemophagocytic lymphohistiocytosis/ sepsis/multiple organ dysfunction
syndrome/macrophage activation syndrome: what is the treatment? Crit
Care 2012;16:R52.
- Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis
and severe sepsis/ systemic inflammatory response syndrome/multiorgan
dysfunction syndrome/macrophage activation syndrome share common
intermediate phenotypes on a spectrum of inflammation. Pediatr Crit
Care Med 2009;10:387-392.
- Betancur JF, Navarro EP, Echeverry A, Moncada PA, Cañas CA, Tobón GJ.
Hyperferritinemic syndrome: Still’s disease and catastrophic
antiphospholipid syndrome triggered by fulminant Chikungunya
infection: a case report of two patients. Clin Rheumatol
2015;34:1989-92.
- Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G,
Rothmann F, et al. Hemophagocytic lymphohistiocytosis in adults:
collaborative analysis of 137 cases of a nationwide German registry. J
Cancer Res Clin Oncol 2020;146:1065-1077.
- Schulert GS, Canna SW. Convergent pathways of the hyperferritinemic
syndromes. Int Immunol 2018;30:195-203.
- Ruscitti P, Cipriani P, Ciccia F, Di Benedetto P, Liakouli V,
Berardicurti O, et al. H-ferritin and CD68(+) /H-ferritin(+)
monocytes/macrophages are increased in the skin of adult-onset Still’s
disease patients and correlate with the multi-visceral involvement of
the disease. Clin Exp Immunol 2016;186:30-8.
- Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y.
The hyperferritinemic syndrome: macrophage activation syndrome,
Still’s disease, septic shock and catastrophic antiphospholipid
syndrome. BMC Med 2013;11:185.
- Carcillo JA, Simon DW, Podd BS. How We Manage Hyperferritinemic
Sepsis-Related Multiple Organ Dysfunction Syndrome/Macrophage
Activation Syndrome/Secondary Hemophagocytic Lymphohistiocytosis
Histiocytosis. Pediatr Crit Care Med 2015;16:598-600.
- Schaffner M, Rosenstein L, Ballas Z, Suneja M. Significance of
Hyperferritinemia in Hospitalized Adults. Am J Med Sci
2017;354:152-158.
- Wang H, Xiong L, Tang W, Zhou Y, Li F. A systematic review of
malignancy-associated hemophagocytic lymphohistiocytosis that needs
more attentions. Oncotarget 2017;8:59977-59985.
- Danhaive O, Caniglia M, Devito R, Piersigilli F, Corchia C, Auriti C.
Neonatal liver failure and haemophagocytic lymphohistiocytosis caused
by a new perforin mutation. Acta Paediatr 2010;99:778-780.
- Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and
outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am
J Hematol 2015;90:220-4.
- Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. Rate of
decline of ferritin in patients with hemophagocytic
lymphohistiocytosis as a prognostic variable for mortality. Pediatr
Blood Cancer 2011;56:154-5.
- La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R,
Berliner N, et al. Recommendations for the management of
hemophagocytic lymphohistiocytosis in adults. Blood
2019;133:2465-2477.
- Romberg N, Vogel TP, Canna SW. NLRC4 inflammasomopathies. Curr Opin
Allergy Clin Immunol 2017;17:398-404.
- Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E,
Choi M, et al. Mutation of NLRC4 causes a syndrome of enterocolitis
and autoinflammation. Nat Genet 2014;46:1135-1139.
- Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary
forms and predisposing conditions. Curr Opin Immunol 2017;49:20-26.
- Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Müller I, Suttorp M,
et al. Malignancy-associated haemophagocytic lymphohistiocytosis in
children and adolescents. Br J Haematol 2015;170:539-49.
- Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al.
Repeated TLR9 stimulation results in macrophage activation
syndrome-like disease in mice. J Clin Invest 2011;121:2264-77.
- Choi YB, Yi DY. Fatal case of hemophagocytic lymphohistiocytosis
associated with group B streptococcus sepsis: A case report. Medicine
(Baltimore). 2018;97:e12210.
- Sağlam B, Albayrak M, Acar A, Yıldız A, Maral S, Tığlıoğlu M, et al. Q
fever as a rare cause of hemophagocytic lymphohistiocytosis: Case
report. Transfus Apher Sci 2020;28:102747.
- Miyoshi Y, Yoshioka S, Gosho H, Miyazoe S, Suenaga H, Aoki M, et al. A
neonatal case of coxsackievirus B3 vertical infection with symptoms of
hemophagocytic lymphohistiocytosis. ID Cases 2020;20:e00738.
- Gavand PE, Serio I, Arnaud L, Costedoat-Chalumeau N, Carvelli J,
Dossier A, et al. Clinical spectrum and therapeutic management of
systemic lupus erythematosus-associated macrophage activation
syndrome: A study of 103 episodes in 89 adult patients. Autoimmun Rev
2017;16:743-749.
- Mărginean MO, Molnar E, Chinceşan MI. Epstein-Barr virus-associated
hemophagocytic lymphohistiocytosis in a small child: A case report.
Medicine (Baltimore) 2020;99:e18759.
- Chuang HC, Lay JD, Hsieh WC, Wang HC, Chang Y, Chuang SE, et al.
Epstein-Barr virus LMP1 inhibits the expression of SAP gene and
upregulates Th1 cytokines in the pathogenesis of hemophagocytic
syndrome. Blood 2005;106:3090-6.
- Hsieh YC, Wu TZ, Liu DP, Shao PL, Chang LY, Lu CY, et al. Influenza
pandemics: past, present and future. J Formos Med Assoc 2006;105:1-6.
- Mao H, Liu Y, Sia SF, Peiris JSM, Lau YL, Tu W. Avian influenza virus
directly infects human natural killer cells and inhibits cell
activity. Virol Sin 2017;32:122-129.
- Brisse E, Wouters CH, Andrei G, Matthys P. How Viruses Contribute to
the Pathogenesis of Hemophagocytic Lymphohistiocytosis. Front Immunol
2017;8:1102.
- Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH,
et al. Confirmed efficacy of etoposide and dexamethasone in HLH
treatment: long-term results of the cooperative HLH-2004 study. Blood
2017;130:2728-2738.
- Gauiran DTV, Cheng PVCY, Pagaduan CRP, Santos MCM.
Autoimmune-Associated Hemophagocytosis and Myelofibrosis in a Newly
Diagnosed Lupus Patient: Case Report and Literature Review. Case Rep
Hematol 2019;2019:3879148.
- Agmon-Levin N, Rosário C, Katz BS, Zandman-Goddard G, Meroni P,
Cervera R, et al. Ferritin in the antiphospholipid syndrome and its
catastrophic variant (cAPS). Lupus 2013;22:1327-35.
- Zandman-Goddard G, Orbach H, Agmon-Levin N, Boaz M, Amital H,
Szekanecz Z, et al. Hyperferritinemia is associated with serologic
antiphospholipid syndrome in SLE patients. Clin Rev Allergy Immunol
2013;44:23-30.
- Campbell CM, Kahwash R. Will Complement Inhibition be the New Target
in Treating COVID-19 Related Systemic Thrombosis? Circulation
2020;[Online ahead of print]. doi:
10.1161/CIRCULATIONAHA.120.047419.
- Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy
and antiphospholipid antibodies in patients with Covid-19. N Engl J
Med 2020;[Online ahead of print]. doi: 10.1056/NEJMc2007575.
- Singer M. The new sepsis consensus definitions (Sepsis-3): the good,
the not-so-bad, and the actually-quite-pretty. Intensive Care Med
2016;42:2027-2029.
- Lachmann G, Knaak C, von Haefen C, Paeschke N, Meisel C, Nyvlt P, et
al. Diagnostic biomarkers for adult haemophagocytic
lymphohistiocytosis in critically ill patients (HEMICU): a prospective
observational study protocol. BMJ Open 2019;9:e032695.
- Simon DW, Halstead ES, Davila S, Kernan KF, Clark RSB, Storch G,
Carcillo JA. DNA Viremia Is Associated with Hyperferritinemia in
Pediatric Sepsis. J Pediatr. 2019 Oct;213:82-87.e2. doi:
10.1016/j.jpeds.2019.06.033.
- Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Berardicurti O,
Carubbi F, et al. H-ferritin and proinflammatory cytokines are
increased in the bone marrow of patients affected by macrophage
activation syndrome. Clin Exp Immunol 2018;191:220-228.
- Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters
DJ, et al. Ferritin functions as a proinflammatory cytokine via
iron-independent protein kinase C zeta/nuclear factor kappaB-regulated
signaling in rat hepatic stellate cells. Hepatology 2009;49:887-900.
- Li R, Luo C, Mines M, Zhang J, Fan GH. Chemokine CXCL12 induces
binding of ferritin heavy chain to the chemokine receptor CXCR4,
alters CXCR4 signaling, and induces phosphorylation and nuclear
translocation of ferritin heavy chain. J Biol Chem 2006;281:37616-27.
- Garcia PC, Longhi F, Branco RG, Piva JP, Lacks D, Tasker RC. Ferritin
levels in children with severe sepsis and septic shock. Acta Paediatr
2007;96:1829-1831.
- Recalcati S, Invernizzi P, Arosio P, Cairo G. New functions for an
iron storage protein: the role of ferritin in immunity and
autoimmunity. J Autoimmun 2008;30:84-89.
- Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin:
past, present and future. Biochim Biophys Acta 2010;1800:760-769.
- Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders
revisited in the hepcidin era. Haematologica 2020;105:260-272.
- ten Kate J, Drenth JP, Kahn MF, van Deursen C. Iron saturation of
serum ferritin in patients with adult onset Still’s disease. J
Rheumatol 2001;28:2213-5.
- Rigamonti L, Ariotti S, Losana G, Gradini R, Russo MA, Jouanguy E, et
al. Surface expression of the IFN-gamma R2 chain is regulated by
intracellular trafficking in human T lymphocytes. J Immunol
2000;164:201-207.
- Weiss G, Goossen B, Doppler W,
Fuchs
D,
Pantopoulos
K,
Werner-Felmayer
G, et al. Translational regulation via iron-responsive elements by the
nitric oxide/NO-synthase pathway. EMBO J 1993;12:3651-3657.
- Brock JH, Mulero V. Cellular and molecular aspects of iron and immune
function. Proc Nutr Soc. 2000;59:537-540.
- Regis G, Bosticardo M, Conti L, De Angelis S, Boselli D, Tomaino B, et
al. Iron regulates T-lymphocyte sensitivity to the IFN-gamma/STAT1
signaling pathway in vitro and in vivo. Blood 2005;105:3214-21.
- Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, et al. SARS
coronavirus entry into host cells through a novel clathrin- and
caveolae-independent endocytic pathway. Cell Res 2008;18:290-301.
- Holger J. Møller. Soluble CD163. Scand J Clin Lab Inv 2012;72:1-13.
- Vishwanath P, Prashant A, Nataraj SM, Kotekar N, Doddamani P: Can
soluble CD163 predict outcome of patients with acute respiratory
distress from mechanical ventilation? A pilot study. Indian J Crit
Care Med 2013:17:355 358.
- Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of
macrophage activation syndrome. Front. Immunol 2019;10:119.
- Schaer D, Schleiffenbaum B, Kurrer M, Imhof A, Bächli E, Fehr J, et
al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a
lineage‐specific marker in the reactive hemophagocytic syndrome. Eur J
Haematol 2005;74:6-10.
- Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage
activation syndrome in patients with systemic juvenile idiopathic
arthritis. J Rheumatol 2007;34:1133-8.
- Sakumura N, Shimizu M, Mizuta M, Inoue N, Nakagishi Y, Yachie A.
Soluble CD163, a unique biomarker to evaluate the disease activity,
exhibits macrophage activation in systemic juvenile idiopathic
arthritis. Cytokine 2018;110:459-65.
- Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank
M, et al. sCD163 in AOSD, a biomarker for macrophage activation
related to hyperferritinemia. Immunol Res 2014;60:177-83.
- Nishino A, Katsumata Y, Kawasumi H, Hirahara S, Kawaguchi Y, Yamanaka
H. Usefulness of soluble CD163 as a biomarker for macrophage
activation syndrome associated with systemic lupus erythematosus.
Lupus 2019;28:986-994.
- Gao Z, Wang Y, Wang J, Zhang J, Wang Z. Soluble ST2 and CD163 as
potential biomarkers to differentiate primary hemophagocytic
lymphohistiocytosis from macrophage activation syndrome. Mediterr J
Hematol Infect Dis 2019;11:e2019008.
- Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like
syndrome: A distinct entity leading to early death in sepsis. Front
Immunol 2019;10:55.
- Shimizu M,
Mizuta
M, Okamoto
N, Yasumi
T, Iwata
N, Umebayashi H, et al. Tocilizumab modifies
clinical and laboratory features of macrophage activation syndrome
complicating systemic juvenile idiopathic arthritis. Pediatric
Rheumatol Online J 2020;18:2.
- Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C. Effect of
tocilizumab on haematological markers implicates interleukin-6
signalling in the anaemia of rheumatoid arthritis. Athritis Res Ther
2013;15:R204.
- Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, KonE’-Paut I, et
al. Effect of biologic therapy on clinical and laboratory features of
macrophage activation syndrome associated with systemic juvenile
idiopathic arthritis. Arthritis Care Res 2018;70:409-419.
- Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload.Ann
N Y Acad Sci 1998;850:191–201.
- Le Lan C, Loréal O, Cohen T, et al. Redox active plasma iron
inC282Y/C282Y hemochromatosis. Blood 2005;105(11):4527–31.
- Temraz S, Santini V, Musallam K, Taher A. Iron overload and chelation
therapy in myelodysplastic syndromes. Crit Rev Oncol Hematol. 2014
Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006.
- Traoré HN, Meyer D. The effect of iron overload on in vitro HIV-1
infection. J Clin Virol 2004;Suppl 1:S92-98.
- van Asbeck BS, Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS,
Marx JJ. Anti-HIV effect of iron chelators: different mechanisms
involved. J Clin Virol 2001;20:141-7.
- Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, van
Asbeck BS. Inhibition of human immunodeficiency virus type 1
replication in human mononuclear blood cells by the iron chelators
deferoxamine, deferiprone, and bleomycin. J Infect Dis
2000;181:484-90.
- Romeo AM, Christen L, Niles EG, Kosman DJ. Intracellular chelation of
iron by bipyridyl inhibits DNA virus replication: ribonucleotide
reductase maturation as a probe of intracellular iron pools. J Biol
Chem 2001;276:24301-8.
- Crowe WE, Maglova LM, Ponka P, Russell JM. Human
cytomegalovirus-induced host cell enlargement is iron dependent. Am J
Physiol Cell Physiol 2004;287:C1023-1030.
- Bayraktar Y, Koseoglu T, Somner C, Kayhan B, Temizer A, Uzunalimoglu
B, et al. The use of deferoxamine infusions to enhance the response
rate to interferon-alpha treatment of chronic viral hepatitis B. J
Viral Hepat 1996;3:129-35.
- Mateos F, González C, Dominguez C, Losa JE, Jimenez A, Pérez-Arellano
JL. Elevated non-transferrin bound iron in the lungs of patients with
Pneumocystis carinii pneumonia. J Infect 1999;38:18-21.
- Arantes JM, Francisco AF, de Abreu Vieira PM, Silva M, Araújo MSS, de
Carvalho AT, et al. Trypanosoma cruzi: desferrioxamine decreases
mortality and parasitemia in infected mice through a trypanostatic
effect. Exp Parasitol 2011;128:401-8.
- Lehmann C, Islam S, Jarosch S, Zhou J, Hoskin D, Greenshields A, et
al. The utility of iron chelators in the management of inflammatory
disorders. Mediators Inflamm 2015;2015:516740.
- Visseren FLJ, Verkerk MSA, van der Bruggen T, Marx JJM, van Asbeck BS,
Diepersloot RJA. Iron chelation and hydroxyl radical scavenging reduce
the inflammatory response of endothelial cells after infection with
Chlamydia pneumoniae or influenza A. Eur J Clin Invest 2002;32 Suppl
1:84-90.
- Kazmierski WM, Wolberg G, Wilson JG, Smith SR, Williams DS, Thorp HH,
et al. Iron chelates bind nitric oxide and decrease mortality in an
experimental model of septic shock. Proc Natl Acad Sci U S A
1996;93:9138-41.
- Wang S, Liu C, Pan S, Miao Q, Xue J, Xun J, et al. Deferoxamine
attenuates lipopolysaccharide-induced inflammatory responses and
protects against endotoxic shock in mice. Biochem Biophys Res Commun
2015;465:305-11.
- Adams PC. Chelation therapy for secondary iron overload: is the
primary effect less iron or less liver fibrosis? Gastroenterology
2011;141:1142-3.
- Adel N, Mantawy EM, El-Sherbiny DA, El-Demerdash E. Iron chelation by
deferasirox confers protection against concanavalin A-induced liver
fibrosis: A mechanistic approach. Toxicol Appl Pharmacol
2019;382:114748.
- Mohammed A, Abd Al Haleem EN, El-Bakly WM, El-Demerdash E.
Deferoxamine alleviates liver fibrosis induced by CCl4 in rats. Clin
Exp Pharmacol Physiol 2016;43:760-768.
- Darwish SF, El-Bakly WM, El-Naga RN, Awad AS, El-Demerdash E.
Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver
fibrosis: Impact on interferon therapy. Biochem Pharmacol
2015;98:231-242.
- Sobbe A, Bridle KR, Jaskowski L, de Guzman CE, Santrampurwala N,
Clouston AD, et al. Inconsistent hepatic antifibrotic effects with the
iron chelator deferasirox. J Gastroenterol Hepatol 2015;30:638-45.
- Tamura K, Uneda K, Azushima K, Wakui H, Haruhara K. Possible
therapeutic impact of the iron chelation on renal fibrosis. Hypertens
Res 2015;38:455-6.
- Ikeda Y, Ozono I, Tajima S, Imao M, Horinouchi Y, Izawa-Ishizawa Y, et
al. Iron chelation by deferoxamine prevents renal interstitial
fibrosis in mice with unilateral ureteral obstruction. PloS One
2014;9:e89355.
- Darwish SF, El-Bakly WM, El-Naga RN, Awad AS, El-Demerdash E.
Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver
fibrosis: Impact on interferon therapy. Biochem Pharmacol
2015;98:231-42.
- Li LF, Huang CC, Liu YY, Lin HC, Kao KC, Yang CT, Liao SK.
Hydroxyethyl starch reduces high stretch ventilation-augmented lung
injury via vascular endothelial growth factor. Transl Res
2011;157:293-305.
- Huang LT, Chou HC, Wang LF, Chen CM. Tissue plasminogen activator
attenuates ventilator-induced lung injury in rats. Acta Pharmacol Sin
2012;33:991-7.
- Weilin Zhu, Yuansi Huang, Yuqiong Ye, Yafeng Wang. Deferoxamine
preconditioning ameliorates mechanical ventilation-induced lung injury
in rat model via ROS in alveolar macrophages: a randomized controlled
study. BMC Anesthesiol 2018;18:116.
- Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi
R, Perricone R, Gerli R. The anti-viral facet of anti-rheumatic drugs:
Lessons from COVID-19. J Autoimmun 2020. in press
https://doi.org/10.1016/j.jaut.2020.102468
- Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in
COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.
Autoimmun Rev. 2020 in press